Signaling pathway networks mined from human pituitary adenoma proteomics data

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  Zhan, Xianquan ^a   Desiderio, Dominic M ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; BIOLOGICAL MARKER; CELL CYCLE PROTEIN;

ADULT; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; ENDOCRINE FUNCTION; ENDOCRINE SYSTEM EXAMINATION; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENITAL SYSTEM DISEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; LIPID METABOLISM; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADENOMA; DATA MINING; ENDOCRINE SYSTEM; GENE REGULATORY NETWORK; GROWTH, DEVELOPMENT AND AGING; HYPOPHYSIS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; MITOCHONDRION; PHYSIOLOGY; PROTEOMICS;

ADENOMA; ADULT; BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; DATA MINING; ENDOCRINE SYSTEM; GENE REGULATORY NETWORKS; HUMANS; LIPID METABOLISM; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PITUITARY GLAND; PITUITARY NEOPLASMS; PROTEIN INTERACTION MAPPING; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 77951557934     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-13     Document Type: Article

References (87)

1. A reference map of a human pituitary adenoma proteome. X Zhan DM Desiderio, Proteomics 2003 3 5 699 713 10.1002/pmic.200300408 12748949 (Pubitemid 36570260)
2. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. CS Moreno CO Evans X Zhan M Okor DM Desiderio NM Oyesiku, Cancer Res 2005 65 22 10214 10222 10.1158/0008-5472.CAN-05-0884 16288009
3. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. CO Evans CS Moreno X Zhan MT McCabe PM Vertino DM Desiderio NM Oyesiku, Pituitary 2008 11 3 231 245 10.1007/s11102-007-0082-2 18183490
4. Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry. X Zhan DM Desiderio, Anal Biochem 2006 354 2 279 289 10.1016/j.ab.2006.05.024 16777052
5. The human pituitary nitroproteome: detection of nitrotyrosylproteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry. X Zhan DM Desiderio, Biochem Biophys Res Commun 2004 325 4 1180 1186 10.1016/j.bbrc.2004.10.169 15555551
6. Linear ion-trap mass spectrometric characterization of human pituitary nitrotyrosine-containing proteins. X Zhan DM Desiderio, Int J Mass Spectrom 2007 259 1-3 96 104 10.1016/j.ijms.2006.06.009
7. A mitochondrial protein compendium elucidates complex I disease biology. DJ Pagliarini SE Calvo B Chang SA Sheth SB Vafai SE Ong GA Walford C Sugiana A Boneh WK Chen DE Hill M Vidal JG Evans DR Thorburn SA Carr VK Mootha, Cell 2008 134 1 112 123 10.1016/j.cell.2008.06.016 18614015
8. Mitochondrial medicine: entering the era of treatment. S Koene J Smeitink, J Intern Med 2009 265 2 193 209 10.1111/j.1365-2796.2008.02058.x 19192036
9. Mitochondria as targets for detection and treatment of cancer. JS Modica-Napolitano KK Singh, Expert Rev Mol Med 2002 4 9 1 19 10.1017/S1462399402004453 14987393
10. Mitochondrial dysfunction in cancer. JS Modica-Napolitano KK Singh, Mitochondrion 2004 4 5-6 755 762 10.1016/j.mito.2004.07.027 16120430
11. Mitochondrial dysfunction in neurodegenerative diseases. AH Schapira, Neurochem Res 2008 33 12 2502 2509 10.1007/s11064-008-9855-x 18998208
12. Mitochondrial dysfunction in cardiovascular disease. SW Ballinger, Free Radic Biol Med 2005 38 10 1278 1295 10.1016/j.freeradbiomed.2005.02.014 15855047
13. Mitochondrial dysfunction in diabetes mellitus. CM Anderson, Drug Dev Res 1999 46 1 67 79 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0. CO;2-V
14. Mitochondrial dysfunction in COPD patients with low body mass index. RA Rabinovich R Bastos E Ardite L Llinas M Orozco-Levi J Gea J Vilaro JA Barbera R Rodriguez-Roisin JC Fernandez-checa J Roca, Eur Respir J 2007 29 4 643 650 10.1183/09031936.00086306 17182653
15. Mitochondrial structural changes and dysfunction are associated with experimental allergic asthma. U Mabaliraja AK Dinda S Kumar R Roshan P Gupta SK Sharma B Ghosh, J Immunol 2008 181 5 3540 3548 18714027
16. Mitochondria in cancer. G Kroemer, Oncogene 2006 25 34 4630 4632 10.1038/sj.onc.1209589 16892077 (Pubitemid 44187613)
17. The biological significance of cancer: Mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. A Halabe Bucay, Med Hypotheses 2007 69 4 826 828 10.1016/j.mehy.2007.02.002 17368752
18. Ultrastructurally abnormal mitochondria in the pituitary oncocytoma. HH Goebel F Schulz B Rama, Acta Neurochir 1980 51 3-4 195 201 10.1007/BF01406745
19. Large mitochondria in a pituitary adenoma with hyperprolactinemia. DS Horoupian, Cancer 1980 46 3 537 542 10.1002/1097-0142(19800801)46:3<537::AID- CNCR2820460319>3.0.CO;2-6 6249483
20. Adrenocortical-pitutiary hybrid tumor causing Cushing's syndrome. N Niroi GP Chrousos B Kohn A Lafferty M Abu-Asab S Bonat A White SR Bornstein, J Clin Endocrinol Metab 2001 86 6 2631 2637 10.1210/jc.86.6.2631 11397864
21. Inhibitory effects of melatonin on the growth of pituitary prolactin-secreting tumor in rats. QH Yang JN Xu RK Xu SF Pang, J Pineal Res 2006 40 3 230 235 10.1111/j.1600-079X.2005.00305.x 16499559
22. Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. W Saeger DK Ludecke M Buchfelder R Fahlbusch HJ Quabbe S Petersenn, Eur J Endocrinol 2007 156 2 203 216 10.1530/eje.1.02326 17287410
23. 'Spindle cell oncotytoma' of the adenohypophysis: a tumor of folliculostellate cells? F Roncaroli BW Scheithauer G Cenacchi E Horvath K Kovacs RV Lloyd P Abell-Aleff M Santi AJ Yates, Am J Surg Pathol 2002 26 1048 1055 10.1097/00000478-200208000-00010 12170092
24. Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. AP John, Med Hypotheses 2001 57 4 429 431 10.1054/mehy.2001.1335 11601863
25. Cancer cell mitochondria are direct proapoptotic targests for the marine antitumor drug lamellarin D. J Kluza MA Gallego A Loyens JC Beauvillain JMF Sousa-Faro C Cuevas P Marchetti C Bailly, Cancer Res 2006 66 6 3177 3187 10.1158/0008-5472.CAN-05-1929 16540669
26. Targeting mitochondria emerges as therapeutic strategy. K Garber, J Natl Cancer Inst 2005 97 24 1800 1801 16368937
27. Mitochondria as therapeutic targets for cancer chemotherapy. L Galluzzi N Larochette N Zamzami G Kroemer, Oncogene 2006 25 34 4812 4830 10.1038/sj.onc.1209598 16892093
28. Mitochondria and human cancer. JS Modica-Napolitano M Kulawiec KK Singh, Cur Mol Med 2007 7 1 121 131 10.2174/156652407779940495 (Pubitemid 46322283)
29. Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria. EL Bell T Klimova NS Chandel, Antioxid Redox Signal 2008 10 3 635 640 10.1089/ars.2007.1655 17999628
30. Oxidative stress: A novel strategy in cancer treatment. VR Tandon S Sharma A Mahajan GH Bardi, J K Science 2005 7 1 1 3
31. Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. S Toyokuni, IUBMB Life 2008 60 7 441 447 10.1002/iub.61 18465793
32. Oxidative stress and cancer: have we moved forward? B Halliwell, Biochem J 2007 401 1 1 11 10.1042/BJ20061131 17150040
33. Nitric oxide synthase in the rat anterior pituitary gland and the role of nitric oxide in regulation of LH secretion. S Ceccatelli AL Hulting X Zhang L Gustafsson M Villar T Hokfelt, Proc Natl Acad Sci USA 1993 90 23 11292 11296 10.1073/pnas.90.23.11292 7504302
34. Neuronal nitric oxide synthase gene expression in human pituitary tumours: a possible association with somatotroph adenomas and growth hormone-releasing hormone gene expression. Y Ueta A Levy MP Powell SL Lightaman Y Kinoshita A Yokota I Shibuya H Yamashita, Clin Endocrinol (Oxf) 1998 49 1 29 38 10.1046/j.1365-2265.1998.00399.x 9797844
35. Nitric oxide synthase in the human pituitary gland. RV Lloyd L Jin X Qian S Zhang BW Scheithauer, Am J Pathol 1995 146 1 86 94 7531951
36. Immunohistochemical demonstration of nitric oxide synthase (NOS) in the normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas. M Pawlikowshi K Winczyk M Jaranowska, Folia Histochem Cytobiol 2003 41 2 87 90 12722794
37. Nitric oxide synthase activity in human pituitary adenomas. A Kruse H Broholm I Rubin K Schmidt M Lauritzen, Acta Neurol Scand 2002 106 6 361 366 10.1034/j.1600-0404.2002.01138.x 12460142
38. Inducible nitric oxide synthase in the anterior pituitary gland: induction by interferon-r in a subpopulation of folliculostellate cells and in an unidentifiable population of nonhormone-secreting cells. H Vankelecom P Matthys C Denef, J Histochem Cytochem 1997 45 6 847 857 9199670
39. Role of nitric oxide in the control of the hypothalamic-pituitary- adrenocortical axis. W Riedel, Z Rheumatol 2002 59 suppl 2 I-36 II-42
40. The role of nitric oxide (NO) in control of LHRH release that mediates gonadotropin release and sexual behavior. SM McCann G Haens C Mastronardi A Walczewska S Karanth V Rettori WH Yu, Curr Pharm Des 2003 9 5 381 390 10.2174/1381612033391766 12570815
41. Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin. SM McCann S Karanth CA Mastronardi WL Dees G Childs B Miller S Sower WH Yu, Arch Med Res 2001 32 6 476 485 10.1016/S0188-4409(01)00343-5 11750723
42. Effects of systemic blockade of nitric oxide synthases on pulsatile LH, prolactin, and GH secretion in adult male rats. L Pinilla LC Gonzalez M Tena-Sempere C Bellido E Aguilar, Horm Res 2001 55 5 229 235 10.1159/000050001 11740144
43. Role of nitric oxide in control of prolactin release by the adenohypophysis. BH Duvilanski C Zambruno A Seilicovich D Pisera M Lasaga MC Diaz N Belova V Rettori SM McCann, Proc Natl Acad Sci USA 1995 92 1 170 174 10.1073/pnas.92.1.170 7529411
44. Nitric oxide stimulates growth hormone secretion in vitro through a calcium- and cyclic guanosine monophosphate-independent mechanism. L Pinilla M Tena-Sempere E Aguilar, Horm Res 1999 51 5 242 247 10.1159/000023378 10559669
45. Nitric oxide modulates in vivo and in vitro growth hormone release in acromegaly. CM Cuttica M Giusti L Bocca P Sessarego D De Martini S Valenti R Spaziante G Giordano, Neuroendocrinology 1997 66 6 426 431 10.1159/000127268 9430448
46. Nitric oxide biphasically modulates GH secretion in cultured cells of GH-secreting human pituitary adenomas. L Bocca S Valenti CM Cuttica R Spaziante G Giordano M Giusti, Minerva Endocrinol 2000 25 3-4 55 59 11338396
47. Free radicals, metals and antioxidants in oxidative stress-induced cancer. M Valko CJ Rhodes J Moncol M Izakovic M Mazur, Chem Biol Interact 2006 160 1 1 40 10.1016/j.cbi.2005.12.009 16430879
48. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking mangese superoxide dismutase. Y Li TT Huang EJ Carlson S Melov PC Ursell JL Olson LJ Noble MP Yoshimura C Berger PH Chan DC Wallace CJ Epstein, Nat Genet 1995 11 4 376 381 10.1038/ng1295-376 7493016
49. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. S Elchuri TD Oberley W Qi RS Eisenstein RL Jackson H Van Remmen CJ Epstein TT Huang, Oncogene 2005 24 3 367 380 10.1038/sj.onc.1208207 15531919
50. Lifepan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutasecatalase mimetics. S Melov SR Doctrow JA Schneider J Haberson M Patel PE Coskun K Huffman DC Wallace B Malfroy, J Neurosci 2001 21 21 8348 8353 11606622
51. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. SW Kang SG Rhee TS Chang W Jeong MH Choi, Trends Mol Med 2005 11 12 571 578 10.1016/j.molmed.2005.10.006 16290020
52. Bacteria-induced intestinal cancer in mice with disrupted GPx1 and Gpx2 genes. FF Chu RS Esworthy PG Chu JA Longmate MM Huycke S Wilczynski JH Doroshow, Cancer Res 2004 64 3 962 968 10.1158/0008-5472.CAN-03-2272 14871826
53. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. CA Neumann DS Krause CV Carman S Das DP Dubey JL Abraham RT Bronson Y Fujiwara SH Orkin RA Van Etten, Nature 2003 424 6948 561 565 10.1038/nature01819 12891360
54. Immunohistochemical study on the expression of copper and zinc-superoxide dismutase (Cu, Zn-SOD) in human adenohypophysis and pituitary adenomas. M Kurisaka T Nakajo K Mori, No To Shinkei 2004 46 10 948 954
55. Molecular mechanisms of Nrf2-mediated antioxidant response. W Li AN Kong, Mol Carcinog 2009 48 2 91 104 10.1002/mc.20465 18618599
56. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. WO Osburn N Wakabayashi V Misra T Nilles S Biswal MA Trush TW Kensler, Arch Biochem Biophys 2006 454 1 7 15 10.1016/j.abb.2006.08.005 16962985
57. Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. J Pi Q Zhang CG Woods V Wong S Collins ME Anderson, Toxicol Appl Pharmacol 2008 226 3 236 243 10.1016/j.taap.2007.09.016 17980396
58. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. S Dhakshinamoorthy AG Porter, J Biol Chem 2004 279 19 20096 20107 10.1074/jbc.M312492200 14985350
59. Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression. GE Mann DJ Rowlands FYL Li P de Winter RCM Siow, Cardiovasc Res 2007 75 2 261 274 10.1016/j.cardiores. 2007.04.004 17498676
60. The role of Keap1 in cellular protective responses. AT Dinkova-Kostova WD Holtzclaw TW Kensler, Chem Res Toxicol 2005 18 12 1779 1791 10.1021/tx050217c 16359168
61. Chemopreventive promise of targeting the Nrf2 pathway. MS Yates TW Kensler, Drug News Perspect 2007 20 2 109 117 10.1358/dnp.2007.20.2.1083437 17440634
62. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. JH Lim KM Kim SW Kim O Hwang HJ Choi, Pharmacol Res 2008 57 5 325 331 10.1016/j.phrs.2008.03.004 18455424
63. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. HE Turner ZS Nagy N Nullivan MM Esiri JAH Wass, Clin Endocrinol 2000 53 3 337 344 10.1046/j.1365-2265.2000.01088.x
64. Cell cycle dysregulation in pituitary oncogenesis. M Musat VV Vax N Borboli M Gueorguiev S Bonner M Korbonits AB Grossman, Front Horm Res 2004 32 34 62 full-text 15281339
65. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. R Yu SG Ren GA Horwitz Z Wang S Melmed, Mol Endocrinol 2000 14 8 1137 1146 10.1210/me.14.8.1137 10935539
66. Proliferation markers and cell cycle inhibitors in pituitary adenomas. W Saeger, Front Horm Res 2004 32 110 126 full-text 15281342
67. Pituitary tumour pathogenesis. AP Heaney, Br Med Bull 2006 75-76 81 97 10.1093/bmb/ldh062 16684928
68. Molecular pathogenesis of pituitary tumors. WE Farrell RN Clayton, Front Neuroendocrinol 2000 21 3 174 198 10.1006/frne.1999.0195 10882539
69. Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. R Yu SG Ren S Melmed, J Endocrinol 2002 174 3 379 386 10.1677/joe.0.1740379 12208657
70. MAP kinase signaling pathways in cancer. AS Dhillon S Hagan O Rath W Kolch, Oncogene 2007 26 22 3279 3290 10.1038/sj.onc.1210421 17496922
71. In melanoma, Ras mutations are accompanied by switching signaling from BRAF to CRAF and discrupted cyclin AMP signaling. N Dumaz R Hayward J Martin L Ogilvie D Hedley JA Curtin BC Bastian C Springer R Marais, Cancer Res 2006 66 19 9483 9491 10.1158/0008-5472.CAN-05-4227 17018604
72. NF-kappa B and JNK: an intricate affair. C Bubici S Papa CG Pham F Zazzeroni G Franzoso, Cell Cycle 2004 3 12 1524 1529 15611622
73. Signal transduction by the JNK group of MAP kinases. RJ Davis, Cell 2000 103 2 239 252 10.1016/S0092-8674(00)00116-1 11057897
74. p38 MAP kinase's emerging role as a tumor suppressor. DV Bulavin AJ Fornace Jr, Adv Cancer Res 2004 92 95 118 full-text 15530558
75. Mitogen-activated protein kinases in apoptosis regulation. T Wada JM Penninger, Oncogene 2004 23 16 2838 2849 10.1038/sj.onc.1207556 15077147
76. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. GL Johnson R Lpadat, Science 2002 298 5600 1911 1912 10.1126/science.1072682 12471242
77. Pharmcological inhibitors of MAPK pathways. JM English MH Cobb, Trends Pharmacol Sci 2002 23 1 40 45 10.1016/S0165-6147(00)01865-4 11804650
78. p38 MAP kinase: a convergence point in cancer therapy. JM Olson AR Hallahan, Trends Mol Med 2004 10 3 125 129 10.1016/j.molmed.2004.01.007 15102355
79. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. L Vallar A Spada G Giannattasio, Nature 1987 330 6148 566 568 10.1038/330566a0 2825031
80. Gs and Gi2 mutations in clinically nonfunctioning pituitary tumors. EA Willamson M Daniels S Foster WF Kelly P Kendall-Taylor PE Harris, Clin Endocrinol (Oxf) 1994 41 5 815 820 10.1111/j.1365-2265.1994.tb02798.x 7889619
81. Ras mutations in human pituitary tumors. HJ Karga JM Alexander ET Hedley-Whyte A Klibanski LJ Jamesom, J Clin Endocrinol Metab 1992 74 4 914 919 10.1210/jc.74.4.914 1312542
82. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. I Ewing S Pedder-Smith G Franchi M Ruscica M Emery V Vax E Garcia S Czirjak Z Hanzely B Kola M Korbonits AB Grossman, Clin Endocrinol (Oxf) 2007 66 3 348 352 10.1111/j.1365-2265.2006.02735.x 17302867
83. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. SL Fougner J Bollerslev F Latif JK Hald T Lund J Ramm-Pettersen JP Berg, J Clin Endocrinol Metab 2008 93 4 1211 1216 10.1210/jc.2007-2272 18230656
84. Novel molecular aspects of pituitary adenomas. E Hubina M Ruscica AM Nanzer S Czirjak MI Goth AB Grossman M Korbonits, J Endocrinol Invest 2005 28 11 Suppl International 87 92 16625855
85. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. JJ An SR Cho DW Jeong KW Park YS Ahn JH Baik, Mol Cell Endocrinol 2003 206 1-2 49 62 10.1016/S0303-7207(03) 00236-3 12943989
86. Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives. X Zhan DM Desiderio, Mass Spectrom Rev 2005 24 6 783 813 10.1002/mas.20039 15495141
87. Expression profile of interferon stimulated genes in central nervous system of mice infected with dengue virus type-1. J Bordignon CM Probst ALP Mosimann DP Pavoni V Stella GA Buck N Satproedprai P Fawcett SM Zanata L de Noronha MA Krieger, Virology 2008 377 2 319 329 10.1016/j.virol.2008.04.033 18570970